Literature DB >> 21139089

Population trends of recurrent coronary heart disease event rates remain high.

Tom G Briffa1, Michael S Hobbs, Andrew Tonkin, Frank M Sanfilippo, Siobhan Hickling, Stephen C Ridout, Matthew Knuiman.   

Abstract

BACKGROUND: Survivors of nonfatal coronary heart disease (CHD) can reduce their risk of further events by various preventive interventions. The impact of such measures as delivered over 11 years, on population rates of subsequent major CHD events, has not been extensively studied. This study determined population trends in the prevalence of clinically manifest CHD and the proportion of major CHD events that occur in this population. METHODS AND
RESULTS: A population longitudinal person-based event-linked file of CHD extracted from State Hospital Morbidity Data and Death Registry for 1980 to 2005 was used to identify, for each year from 1995 to 2005, survivors who had a hospitalization for CHD over the previous 15 years (population with established CHD), and to examine the occurrence of CHD death and hospitalization with a principal diagnosis of myocardial infarction in both populations with and without established CHD. The average annual age-standardized prevalence of CHD in the Perth metropolitan region (population 1.6 million) was 28 373 (8.8%) in men and 14 966 (4.0%) in women. Age-specific prevalence increased exponentially with age, from <1% in 35 to 39 age group to 42% in 80 to 84 age group in men and half that in women. The percentage of total CHD events (n=28 941) that occurred in the population with established CHD was approximately 43% in both men and women, 55% and 51%, respectively, for CHD death and 35% and 36% for nonfatal myocardial infarction.
CONCLUSIONS: More than 40% of major CHD events annually occur in persons with manifest disease, highlighting the imperative to implement systems of care that support effective secondary prevention.

Entities:  

Mesh:

Year:  2010        PMID: 21139089     DOI: 10.1161/CIRCOUTCOMES.110.957944

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  30 in total

Review 1.  Relationships between positive psychological constructs and health outcomes in patients with cardiovascular disease: A systematic review.

Authors:  Christina M DuBois; Oriana Vesga Lopez; Eleanor E Beale; Brian C Healy; Julia K Boehm; Jeff C Huffman
Journal:  Int J Cardiol       Date:  2015-05-21       Impact factor: 4.164

Review 2.  Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.

Authors:  Richard Kones
Journal:  Drug Des Devel Ther       Date:  2011-06-13       Impact factor: 4.162

3.  Inhibition of p53-p21 pathway promotes the differentiation of rat bone marrow mesenchymal stem cells into cardiomyocytes.

Authors:  Xuebo Yan; Anlin Lv; Yujie Xing; Bowu Liu; Jing Hou; Wei Huang; Yao Li
Journal:  Mol Cell Biochem       Date:  2011-04-06       Impact factor: 3.396

4.  Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2022-08-23

5.  Budget Impact Analysis of Pharmacist-Led Medication Management in Cardiovascular and Type 2 Diabetic Patients.

Authors:  Iva Mucalo; Andrea Brajković; Marija Strgačić; Djenane Ramalho-de-Oliveira; Elizabeta Ribarić; Ana Bobinac
Journal:  Healthcare (Basel)       Date:  2022-04-13

6.  Cardiovascular risk assessment in elderly individuals without overt CVD disease. Could traditional risk factors fit in all ages?

Authors:  Areti Triantafyllou; Stella Douma
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-07-11       Impact factor: 3.738

7.  Are We Optimizing the Use of Dual Antiplatelet Therapy in Patients Hospitalized with Acute Myocardial Infarction?

Authors:  Essa Hariri; Darleen Lessard; Joel Gore; Jeffrey Rade; Robert Goldberg
Journal:  Cardiovasc Revasc Med       Date:  2019-05-02

8.  Effects of Bilberry and Oat intake on lipids, inflammation and exercise capacity after Acute Myocardial Infarction (BIOAMI): study protocol for a randomized, double-blind, placebo-controlled trial.

Authors:  Cecilia Bergh; Rikard Landberg; Kristina Andersson; Lovisa Heyman-Lindén; Ana Rascón; Anders Magnuson; Payam Khalili; Amra Kåregren; Johan Nilsson; Carlo Pirazzi; David Erlinge; Ole Fröbert
Journal:  Trials       Date:  2021-05-10       Impact factor: 2.279

9.  Prescription of secondary prevention medications, lifestyle advice, and referral to rehabilitation among acute coronary syndrome inpatients: results from a large prospective audit in Australia and New Zealand.

Authors:  Julie Redfern; Karice Hyun; Derek P Chew; Carolyn Astley; Clara Chow; Bernadette Aliprandi-Costa; Tegwen Howell; Bridie Carr; Karen Lintern; Isuru Ranasinghe; Kellie Nallaiah; Fiona Turnbull; Cate Ferry; Chris Hammett; Chris J Ellis; John French; David Brieger; Tom Briffa
Journal:  Heart       Date:  2014-06-09       Impact factor: 5.994

10.  Treatment pattern of contemporary dual antiplatelet therapies after acute coronary syndrome: a Swedish nationwide population-based cohort study.

Authors:  Oskar Angerås; Pål Hasvold; Marcus Thuresson; Anna Deleskog; Oscar ÖBraun
Journal:  Scand Cardiovasc J       Date:  2015-12-11       Impact factor: 1.589

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.